Cat. No. 5173
Chemical Name: (E)-4-[2-(2-Amino-4-hydroxy-5-methy
Biological ActivityPotent and selective BRD4 bromodomain inhibitor (Ki = 30 - 50 nM for the first bromodomain (BRD4(1)). Exhibits 10-fold selectivity for BRD4(1) over BRD4(2). Blocks BRD4 transcriptional activity in lipopolysaccharide-induced production of both nitric oxide and IL-6 in mouse macrophages (IC50 values are 3.8 and 4.9 μM, respectively). Attenuates melanoma cell proliferation in vitro.
Licensing InformationSold under license from Icahn School of Medicine at Mount Sinai.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Segura et al (2013) BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 73 6264. PMID: 23950209.
Zhang et al (2013) Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J.Med.Chem. 56 9251. PMID: 24144283.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses MS 436 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MS 436, supplier, MS436, potent, selective, BRD4, BrD1, Bromodomain, inhibitors, inhibits, BrD2, gene, transcription, transcriptional, epigenetics, BRD4(1), Tocris Bioscience, Bromodomain Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective inhibitor of cat eye syndrome chromosome region, candidate 2 (CECR2)NI 42
High affinity BRPF inhibitorBI 9564
Potent and selective BRD9 and BRD7 inhibitor; orally activeISOX DUAL
Dual BRD4 and CBP/p300 bromodomain inhibitorISOX INACT
Negative control for PF-CBP1 (Cat. No. 5801)
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.